Sequent Scientific has partnered with Gilead Sciences Inc whereby the latter has licensed Sequent to produce active pharmaceutical ingredients (APIs) sofosbuvir and ledipasvir for treatment of chronic Hepatitis C. Under the agreement, Sequent will receive a complete technology pack from Gilead to enable scale up production of the APIs as quickly as possible. The formulations using these APIs can be distributed in 91 developing countries, which account for more than 100 million people living with Hepatitis C, globally representing 54% of the total global infected population.
Sofosbuvir was approved under the trade name Sovaldi by the US Food and Drug Administration (USFDA) in December 2013 and by the European Commission in January 2014. The USFDA and the European Medicines Agency are currently reviewing Gilead’s applications for a single tablet regimen of ledipasvir/sofosbuvir; it is an investigational agent and its safety and efficacy have not been established.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
